Natera（NTRA）株式概要
診断薬会社であるNatera, Inc.は、世界中で分子検査サービスの開発と商業化に従事している。 詳細
NTRA Community Fair Values
Create NarrativeSee what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Natera, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$271.49 |
| 52週高値 | US$275.24 |
| 52週安値 | US$131.81 |
| ベータ | 1.54 |
| 1ヶ月の変化 | 21.54% |
| 3ヶ月変化 | 33.60% |
| 1年変化 | 68.92% |
| 3年間の変化 | 456.90% |
| 5年間の変化 | 130.29% |
| IPOからの変化 | 1,093.89% |
最新ニュース
Seeking Alpha • Jun 26
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise
Summary Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable with a high forward P/S of ~14x. Core drivers include surging test volumes in oncology and women's health, with standout performance from the Signatera MRD platform and recent regulatory wins. Despite strong fundamentals and expanding addressable markets, NTRA’s valuation appears stretched, reflecting high investor expectations for sustained hyper-growth. I assign a Hold rating, citing premium pricing and the risk that future revenue growth may not match current market optimism. Read the full article on Seeking Alpha
ナラティブの更新 • Jun 22
NTRA: MRD Guideline Tailwinds Will Support 2026 Catalyst Heavy Outlook
The analyst price target for Natera has edged down slightly to $260.05 from about $260.89, as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E. They also highlight the potential uptake of Signatera following new NCCN guideline support and a continued focus on minimal residual disease testing adoption and reimbursement.分析記事 • Jun 20
Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data
Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...Recent updates
Seeking Alpha • Jun 26
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise
Summary Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable with a high forward P/S of ~14x. Core drivers include surging test volumes in oncology and women's health, with standout performance from the Signatera MRD platform and recent regulatory wins. Despite strong fundamentals and expanding addressable markets, NTRA’s valuation appears stretched, reflecting high investor expectations for sustained hyper-growth. I assign a Hold rating, citing premium pricing and the risk that future revenue growth may not match current market optimism. Read the full article on Seeking Alphaナラティブの更新 • Jun 22
NTRA: MRD Guideline Tailwinds Will Support 2026 Catalyst Heavy Outlook
The analyst price target for Natera has edged down slightly to $260.05 from about $260.89, as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E. They also highlight the potential uptake of Signatera following new NCCN guideline support and a continued focus on minimal residual disease testing adoption and reimbursement.分析記事 • Jun 20
Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data
Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...
ナラティブの更新 • Jun 05
NTRA: MRD Leadership And FDA Approval Will Support Long-Term Trajectory
Analysts have made a modest adjustment to their outlook on Natera, with the average price target moving slightly and recent commentary highlighting the company’s position in molecular residual disease testing. Firms have set a range of targets from $245 to $260 as they balance growth reinvestment with expectations for future operating leverage.ナラティブの更新 • May 22
NTRA: Molecular Residual Disease Leadership Will Support 2026 Catalyst Heavy Outlook
Natera's updated analyst price target has edged higher to about $261 from roughly $259, as analysts factor in a slightly higher fair value, a modestly adjusted discount rate and revenue growth outlook, and a stronger expected profit margin alongside a lower future P/E assumption. Analyst Commentary Recent Street research on Natera shows active recalibration of price targets, with several bullish revisions offset by a smaller number of trims.分析記事 • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...ナラティブの更新 • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
ナラティブの更新 • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.ナラティブの更新 • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.ナラティブの更新 • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.ナラティブの更新 • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.ナラティブの更新 • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.ナラティブの更新 • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.ナラティブの更新 • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.ナラティブの更新 • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.ナラティブの更新 • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.ナラティブの更新 • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.ナラティブの更新 • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.ナラティブの更新 • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.ナラティブの更新 • Oct 27
Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.ナラティブの更新 • Sep 28
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.ナラティブの更新 • Sep 04
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.分析記事 • Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...株主還元
| NTRA | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 15.6% | 6.1% | 0.3% |
| 1Y | 68.9% | 40.6% | 19.9% |
業界別リターン: NTRA過去 1 年間で40.6 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: NTRA過去 1 年間で19.9 % の収益を上げたUS市場を上回りました。
価格変動
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: NTRA 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: NTRAの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2003 | 6,138 | Steve Chapman | www.natera.com |
診断薬会社であるNatera, Inc.は、分子検査サービスの開発と商業化を世界中で行っている。過去にがんと診断された患者のMRD評価、早期再発モニタリング、治療反応性評価のための個別化ctDNA血液検査であるSignatera、血液ベースの大腸がんMRD検査であるLatitude、組織ベースの包括的ゲノムプロファイリング検査であるAltera、遺伝性がんスクリーニング検査であるEmpowerを提供している。また、非侵襲的出生前検査であるPanorama、キャリアスクリーニング検査であるHorizon、21の単一遺伝子の遺伝性疾患をスクリーニングする単一遺伝子NIPT（sgNIPT）であるFetal Focus、25の単一遺伝子の疾患をスクリーニングする単一遺伝子NIPTであるVistaraも提供している。さらに、1回以上の妊娠損失を経験した女性の流産組織を検査・分析するAnora、遺伝性がんスクリーニング検査であるEmpower、固形臓器移植を受けた患者の活動性拒絶反応を評価する検査であるProspera、腎臓遺伝子パネル検査であるRenasight、クラウドベースの販売モデルであるConstellationソフトウェアを提供している。さらに、患者と医療提供者の体験をサポートするプラットフォームNateraCore、瀉血サービス、EMR統合サービスを提供している。同社は、直販部隊や検査施設販売パートナーを通じて、独立系検査施設、全国および地域の基準検査施設、医療センターや医師によるスクリーニング検査、研究検査施設、製薬会社、そしてクラウドベースの販売モデルによるConstellationのライセンシーにサービスを提供している。同社はBGI Genomics Co., Ltd.とパートナーシップ契約を結んでおり、臨床用および商業用のNGSベースの遺伝子検査アッセイを開発、製造、商品化している。ディアコノス・オンコロジー社とは、難治性メラノーマ患者の分子応答を評価するための共同研究を行っている。同社は以前Gene Security Network, LLCとして知られていたが、2012年1月にNatera, Inc.に社名を変更した。は2003年に設立され、テキサス州オースティンに本社を置いている。
Natera, Inc. 基礎のまとめ
| NTRA 基礎統計学 | |
|---|---|
| 時価総額 | US$39.00b |
| 収益（TTM） | -US$226.31m |
| 売上高(TTM) | US$2.50b |
15.5x
P/Sレシオ-171.8x
PER（株価収益率NTRA は割高か？
公正価値と評価分析を参照収益と収入
| NTRA 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.50b |
| 売上原価 | US$873.68m |
| 売上総利益 | US$1.63b |
| その他の費用 | US$1.85b |
| 収益 | -US$226.31m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.58 |
| グロス・マージン | 65.07% |
| 純利益率 | -9.05% |
| 有利子負債／自己資本比率 | 4.5% |
NTRA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/30 00:59 |
| 終値 | 2026/06/30 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Natera, Inc. 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。31
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |